What is the therapeutic effect of Acotiamide?
Since Acotiamide was launched in Japan in 2013, its efficacy and safety have been widely verified in clinical practice. As a special drug for functional dyspepsia (FD), it is mainly used to relieve symptoms such as postprandial fullness, bloating and early satiety. Research and clinical observations show that the efficacy of acotiamide is mainly reflected in improving gastric motility, accelerating gastric emptying and improving patients' postprandial comfort. After using it for a period of time, patients often feel less full, their food intake gradually returns to normal, and their quality of daily life is also improved.
Compared with traditional prokinetic drugs, acotiamide has the advantage of novel mechanism and better tolerance. It inhibits acetylcholinesterase and enhances the action of acetylcholine in the gastrointestinal tract, thereby improving gastric contraction and emptying capabilities. Clinicians found during long-term follow-up that the drug is particularly effective for patients with "postprandial distress syndrome". For patients with functional dyspepsia accompanied by anxiety or emotional factors, acotiamide can also indirectly improve their quality of life.
Of course, acotiamide is not equally effective in all patients. Some patients may not respond well to drugs due to a longer course of the disease or complications such as gastroesophageal reflux. In addition, although the overall safety profile is high, mild adverse reactions such as dizziness, diarrhea, or mild nausea may occur. These are usually short-lived and will not affect long-term treatment. Compared with the cardiovascular side effects that are prone to occur with some traditional drugs, acotiamide has a lower risk, which is also the advantage of its long-term use.
Overall, the therapeutic effect of acotiamide is representative in the field of functional dyspepsia, and it provides a reliable choice for clinical practice. Especially when other drugs are ineffective, acotiamide can often bring significant improvement.
Reference: https://www.rad-ar.or.jp/siori/english/search/result?n=33322
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)